The European Commission has referred Eisai and Biogen’s application to an appeals committee. Elsewhere, Opthea warned of ...
Sanofi has returned to Nurix Therapeutics for another autoimmune candidate, paying $15 million and committing up to $465 ...
Nurix Therapeutics has widened its collaboration with Sanofi, granting the French pharmaceutical company an exclusive license to an undisclosed program targeting a previously undruggable transcription ...
The undisclosed target is a central regulator of inflammation that is distinct from the previously disclosed STAT6 programNurix DEL-AI drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback